Cerus reports preliminary Q4 product revenue $16.2M, consensus $14.9M
Cerus Corporation announced unaudited preliminary product revenue for Q4 and FY17. Cerus' unaudited preliminary product revenue for Q4 was $16.2M, an increase of 60% compared to fourth quarter of 2016. Driving the growth was an increase in global demand for INTERCEPT platelet kits of more than 100%. Preliminary results in the quarter reflect the initial rollout for broad use of the INTERCEPT Blood Systems for platelets in France. Based on the fourth quarter unaudited preliminary product revenue, the company expects full year 2017 product revenue to be $43.6M representing an increase of 17% compared to prior year product revenue. Consensus $43.06M. The preliminary product revenue results reported have not been audited and are subject to change. Cerus will provide complete Q4 and FY17 financial results and host a call in early March.